AGRN Conjugated Antibody

Catalog No: #C37092

SAB Signalway Antibody

Package Size: #C37092-AF350 100ul #C37092-AF405 100ul #C37092-AF488 100ul

#C37092-AF555 100ul #C37092-AF594 100ul #C37092-AF647 100ul

#C37092-AF680 100ul #C37092-AF750 100ul #C37092-Biotin 100ul

Orders: order@signalwayantibody.com Support: tech@signalwayantibody.com

Description

Product Name	AGRN Conjugated Antibody
Host Species	Rabbit
Clonality	Polyclonal
Species Reactivity	Hu
Specificity	The antibody detects endogenous levels of total AGRN protein.
Immunogen Description	Synthetic peptide corresponding to a region derived from internal residues of human agrin
Conjugates	Biotin AF350 AF405 AF488 AF555 AF594 AF647 AF680 AF750
Other Names	AGRIN; agrin proteoglycan; AGRN; FLJ45064
Accession No.	Swiss-Prot#:O00468 NCBI Gene ID:375790NCBI Protein#:NP_705841
Uniprot	O00468
GeneID	375790;
Excitation Emission	AF350: 346nm/442nm
	AF405: 401nm/421nm
	AF488: 493nm/519nm
	AF555: 555nm/565nm
	AF594: 591nm/614nm
	AF647: 651nm/667nm
	AF680: 679nm/702nm
	AF750: 749nm/775nm
Formulation	0.01M Sodium Phosphate, 0.25M NaCl, pH 7.6, 5mg/ml Bovine Serum Albumin, 0.02% Sodium Azide
Storage	Store at 4°C in dark for 6 months

Application Details

Suggested Dilution:

AF350 conjugated: most applications: 1: 50 - 1: 250
AF405 conjugated: most applications: 1: 50 - 1: 250
AF488 conjugated: most applications: 1: 50 - 1: 250
AF555 conjugated: most applications: 1: 50 - 1: 250
AF594 conjugated: most applications: 1: 50 - 1: 250
AF647 conjugated: most applications: 1: 50 - 1: 250
AF680 conjugated: most applications: 1: 50 - 1: 250
AF750 conjugated: most applications: 1: 50 - 1: 250

 $Biotin \ conjugated: working \ with \ enzyme-conjugated \ streptavidin, \ most \ applications: \ 1:50 - 1:1,000$

Background

This gene encodes one of several proteins that are critical in the development of the neuromuscular junction (NMJ), as identified in mouse knock-out studies. The encoded protein contains several laminin G, Kazal type serine protease inhibitor, and epidermal growth factor domains. Additional post-translational modifications occur to add glycosaminoglycans and disulfide bonds. In one family with congenital myasthenic syndrome affecting limb-girdle muscles, a mutation in this gene was found.

Note: This product is for in vitro research use only